Global Personalized Medicine Partnering Deals Analysis 2010-2015: Trends, Players, Financials and Forecasts for Over 1000 Deals
DUBLIN, June 08, 2015 /PRNewswire/ -- Research and Markets (http://www.researchandmarkets.com/research/68qtk8/global) has announced the addition of the "Global Personalized Medicine Partnering 2010-2015: Deal trends, players, financials and forecasts" report to their offering.
The report provides a detailed understanding and analysis of how and why companies enter personalized medicine partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors personalized medicine technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.
Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases do not.
This report contains over 1000 links to online copies of actual personalized medicine deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.
Key Topics Covered:
Executive Summary
Chapter 1 - Introduction
Chapter 2 - Trends in personalized medicine dealmaking
Chapter 3 - Average financial deal terms for personalized medicine partnering
Chapter 4 - Leading biomarker deals
Chapter 5 - Leading companion diagnostic deals
Chapter 6 - Leading pharmacogenomics deals
Chapter 7 - Big pharma personalized medicine deals
Chapter 8 - Biomarker contracts dealmaking directory
Chapter 9 - Companion diagnostic contracts dealmaking directory
Chapter 10 - Pharmacogenomics contracts dealmaking directory
Chapter 11 - Personalized medicine dealmaking directory by specific technology type
Chapter 12 - Future trends and companies in personalized medicine deal making
For more information visit http://www.researchandmarkets.com/research/68qtk8/global
Media Contact: Laura Wood , +353-1-481-1716, press@researchandmarkets.net
Share this article